

### III. Statements of Income

#### 1. Statements of Income

(Billions of Yen)

	FY08	FY09	FY10	FY11	Estimate FY12	FY2011 1-2Q Total	FY2012 1-2Q Total	vs. FY2011 1-2Q Total	increase/ decrease	Est. FY12 in May	increase/ decrease
<b>Net Sales</b>	1,538.3	1,466.0	1,419.4	1,508.9	1,550.0	702.5	<b>786.9</b>	84.4	12.0%	1,550.0	-
<Royalty income>	<55.7>	<45.4>	<41.4>	<42.5>		<20.8>	<b>&lt;20.4&gt;</b>	<-0.4>	<-1.8%>		
Pharmaceuticals	1,448.5										
Ethical drugs	1,384.1	1,317.7	1,267.4	1,358.8	1,400.0	627.0	<b>710.4</b>	83.4	13.3%	1,400.0	-
Consumer Healthcare	64.4	58.2	60.3	61.7		31.8	<b>33.6</b>	1.8	5.6%		
Others	89.9										
Others		94.8	96.3	93.1		46.0	<b>45.2</b>	-0.8	-1.6%		
Adjustments		-4.8	-4.6	-4.6		-2.3	<b>-2.3</b>	0.1			
<b>Cost of sales</b>	289.5	285.1	317.6	433.2		159.6	<b>216.1</b>	56.5	35.4%		
<% of net sales>	<18.8%>	<19.4%>	<22.4%>	<28.7%>		<22.7%>	<b>&lt;27.5%&gt;</b>	<4.7pt>			
<b>Gross Profit</b>	1,248.8	1,180.9	1,101.8	1,075.7		542.9	<b>570.9</b>	27.9	5.1%		
<% of net sales>	<81.2%>	<80.6%>	<77.6%>	<71.3%>		<77.3%>	<b>&lt;72.5%&gt;</b>	<-4.7pt>			
<b>SG&amp;A expenses</b>	942.3	760.7	734.7	810.7		331.9	<b>462.3</b>	130.4	39.3%		
<% of net sales>	<61.3%>	<51.9%>	<51.8%>	<53.7%>		<47.2%>	<b>&lt;58.7%&gt;</b>	<11.5pt>			
<R&D expenses>	<453.0>	<296.4>	<288.9>	<281.9>	<310.0>	<119.0>	<154.7>	<35.7>	<30.0%>	<310.0>	<->
<b>Operating income</b>	306.5	420.2	367.1	265.0	160.0	211.0	<b>108.6</b>	-102.5	-48.6%	160.0	-
<% of net sales>	<19.9%>	<28.7%>	<25.9%>	<17.6%>	<10.3%>	<30.0%>	<b>&lt;13.8%&gt;</b>	<-16.2pt>		<10.3%>	<->
Pharmaceuticals	296.9										
<% of Pharmaceutical sales>	<20.5%>										
Ethical drugs		400.6	346.0	243.8		198.4	<b>95.3</b>	-103.0	-51.9%		
<% of Ethical drugs>		<30.4%>	<27.3%>	<17.9%>		<31.6%>	<b>&lt;13.4%&gt;</b>	<-18.2pt>			
Consumer Healthcare		11.0	12.2	11.8		7.5	<b>8.4</b>	1.0	13.4%		
<% of Consumer healthcare>		<19.0%>	<20.3%>	<19.2%>		<23.4%>	<b>&lt;25.1%&gt;</b>	<1.7pt>			
Others	9.5										
<% of others sales>	<10.5%>										
Others		10.8	11.0	11.7		6.3	<b>5.8</b>	-0.5	-8.3%		
<% of others sales>		<11.4%>	<11.4%>	<12.6%>		<13.8%>	<b>&lt;12.9%&gt;</b>	<-0.9pt>			
Adjustments		-2.2	-2.2	-2.2		-1.1	<b>-1.0</b>	0.1			
<b>Non-operating income / expenses</b>	20.7	-4.4	4.5	5.3	-10.0	-1.5	<b>4.5</b>	6.0	-	-10.0	-
<b>Non-operating income</b>	43.1	25.2	30.4	23.4		13.4	<b>13.4</b>	0.1	0.6%		
Interest income	11.4	2.0	1.7	1.9		1.0	<b>0.5</b>	-0.5			
Dividend income	5.7	4.2	4.5	4.4		2.2	<b>2.2</b>	0.1			
Equity in earnings of unconsolidated subsidiaries and affiliates	2.9	0.8	0.5	0.3		0.1	<b>0.5</b>	0.4			
Other non-operating income	23.2	18.2	23.8	16.8		10.2	<b>10.2</b>	0.1			
<b>Non-operating expenses</b>	22.4	29.6	25.9	18.1		14.9	<b>8.9</b>	-5.9	-39.9%		
Interest expenses	1.6	1.4	1.3	1.9		0.6	<b>1.5</b>	0.9			
Other non-operating expenses	20.7	28.2	24.6	16.2		14.3	<b>7.4</b>	-6.9			
<b>Ordinary income</b>	327.2	415.8	371.6	270.3	150.0	209.6	<b>113.1</b>	-96.5	-46.0%	150.0	-
<% of net sales>	<21.3%>	<28.4%>	<26.2%>	<17.9%>	<9.7%>	<29.8%>	<b>&lt;14.4%&gt;</b>	<-15.5pt>		<9.7%>	<->
<b>Extraordinary gain and loss</b>	71.3	-	-	-17.9		-	<b>17</b>	<b>17</b>			
<b>Income before income tax and minority interests</b>	398.5	415.8	371.6	252.5		209.6	<b>130.3</b>	-79.2	-37.8%		
Income taxes	161.4	115.7	121.3	125.2		72.1	<b>9.1</b>	-63.0	-87.4%		
Minority interests	2.8	2.4	2.4	3.1		1.8	<b>1.4</b>	-0.3	△18.9%		
<b>Net income</b>	234.4	297.7	247.9	124.2	155.0	135.7	<b>119.8</b>	-15.9	-11.7%	155.0	-
<% of net sales>	<15.2%>	<20.3%>	<17.5%>	<8.2%>	<10.0%>	<19.3%>	<b>&lt;15.2%&gt;</b>	<-4.1pt>		<10.0%>	<->
<b>Comprehensive income &lt;incl. minority interests&gt;</b>	-	255.8	114.5	65.4		-32.2	-19.0	13.2	-41.1%		
<b>Effective tax rate</b>											
Japanese statutory tax rate	40.9%	40.9%	40.9%	40.6%		40.6%	<b>38.0%</b>	-2.6pt			
Effective tax rate	40.5%	27.8%	32.7%	49.6%		34.4%	<b>7.0%</b>	-27.4pt			

\* Effective from the FY2010, the Accounting Standard for Disclosures about Segments of an Enterprise and Related Information has been adopted. The figures for "FY09" are calculated and indicated after applying said accounting standard.

## 2. Sales

### ◆ Sales by Regions

(Billions of Yen)

	FY08	FY09	FY10	FY11	FY2011 1-2Q Total	FY2012 1-2Q Total	vs FY2011 1-2Q Total	increase/ decrease
<b>Total consolidated sales</b>	1,538.3	1,466.0	1,419.4	1,508.9	702.5	<b>786.9</b>	84.4	12.0%
Domestic	695.2	688.9	721.3	733.4	367.0	<b>368.3</b>	1.3	0.3%
Overseas	843.1	777.0	698.1	775.5	335.5	<b>418.7</b>	83.2	24.8%
<% of consolidated net sales>	<54.8%>	<53.0%>	<49.2%>	<51.4%>	<47.8%>	<b>&lt;53.2%&gt;</b>	<5.4pt>	
Americas		561.8	496.4	464.4	233.9	<b>231.3</b>	-2.7	-1.1%
<% of consolidated net sales>		<38.3%>	<35.0%>	<30.8%>	<33.3%>	<b>&lt;29.4%&gt;</b>	<-3.9pt>	
[U.S.]		[544.5]	[483.4]	[419.5]	[226.5]	<b>[193.8]</b>	[-32.7]	[-14.4%]
[Latin America]				[30.2]	[2.4]	<b>[29.4]</b>	[27.0]	-
Europe		189.1	172.9	258.0	83.4	<b>[147.7]</b>	64.2	77.0%
<% of consolidated net sales>		<12.9%>	<12.2%>	<17.1%>	<11.9%>	<b>&lt;18.8%&gt;</b>	<6.9pt>	
[Russia/CIS]				[31.0]	[0.0]	<b>[29.5]</b>	[29.5]	-
Asia and other regions		26.1	28.7					
<% of consolidated net sales>		<1.8%>	<2.0%>					
Asia				38.1	13.7	<b>[28.9]</b>	15.2	110.8%
<% of consolidated net sales>				<2.5%>	<1.9%>	<b>&lt;3.7%&gt;</b>	<1.7pt>	
Other				15.0	4.5	<b>[10.9]</b>	6.4	143.2%
<% of consolidated net sales>				<1.0%>	<0.6%>	<b>&lt;1.4%&gt;</b>	<0.7pt>	
Royalty income	55.7	45.4	41.4	42.5	20.8	<b>20.4</b>	-0.4	-1.8%
Ethical drugs		45.1	41.0	42.2	20.6	<b>20.3</b>	-0.3	-1.7%
Domestic		0.1	0.7	0.4	0.1	<b>0.3</b>	0.2	146.0%
Overseas		44.9	40.3	41.8	20.5	<b>20.0</b>	-0.5	-2.4%

\* Effective from the FY2010, the Accounting Standard for Disclosures about Segments of an Enterprise and Related Information has been adopted.

The figures for "FY09" are calculated and indicated after applying said accounting standard.

\*\* Effective from the FY2012, the Company changed the classification of region for the purpose of providing more detailed sales information (previous "Asia and other regions" was divided into "Asia" and "Other"). In addition, two regions ("Latin America" in "Americas" and "Russia/CIS" in "Europe") were newly added. For fair comparison, the amounts reported in the FY2011 are modified according to the new classification. In addition, the regional category of some countries in other than Americas was also changed as this reclassification.

\*\*\* "Other" region includes Middle East, Oceania and Africa.

### ◆ Ethical Drugs Sales [Consolidated basis]

(Billions of Yen)

	FY08	FY09	FY10	FY11	FY2011 1-2Q Total	FY2012 1-2Q Total	vs FY2011 1-2Q Total	increase/ decrease
<b>Domestic sales</b>		551.7	580.5	594.4	297.3	<b>297.2</b>	-0.0	-0.0%
<b>Overseas sales</b>		719.1	645.5	720.0	307.9	<b>392.0</b>	84.1	27.3%
Americas		535.2	475.4	447.1	223.8	<b>223.4</b>	-0.4	-0.2%
[U.S.]				[407.3]	[219.0]	<b>[186.3]</b>	[-32.7]	[-14.9%]
[Latin America]				[29.9]	[2.2]	<b>[29.2]</b>	[27.0]	-
Europe		163.4	146.7	225.7	68.8	<b>131.8</b>	63.0	91.6%
[Russia/CIS]				[30.9]	[0.0]	<b>[29.5]</b>	[29.5]	-
Asia and other regions		20.5	23.4					
Asia				33.6	11.5	<b>26.6</b>	15.1	131.2%
Other				13.6	3.8	<b>10.2</b>	6.4	168.3%
<b>Royalty income and service income</b>		50.2	44.5	47.7	23.6	<b>22.8</b>	-0.8	-3.5%
Domestic		0.6	1.0	1.0	0.5	<b>0.6</b>	0.2	35.1%
Overseas		49.6	43.5	46.6	23.1	<b>22.1</b>	-1.0	-4.3%
<b>Total sales</b>		1,321.1	1,270.5	1,362.0	628.7	<b>712.0</b>	83.2	13.2%
<b>Ratio of overseas sales</b>		58.2%	54.2%	56.3%	52.6%	<b>58.2%</b>	<5.5pt>	

\* Sales amount includes intersegment sales.

\*\* Effective from the FY2010, the Accounting Standard for Disclosures about Segments of an Enterprise and Related Information has been adopted.

The figures for "FY09" are calculated and indicated after applying said accounting standard.

\*\*\* Effective from the FY2012, the Company changed the classification of region for the purpose of providing more detailed sales information (previous "Asia and other regions" was divided into "Asia" and "Other"). In addition, two regions ("Latin America" in "Americas" and "Russia/CIS" in "Europe") were newly added. For fair comparison, the amounts reported in the FY2011 are modified according to the new classification. In addition, the regional category of some countries in other than Americas was also changed as this reclassification.

\*\*\*\* "Other" region includes Middle East, Oceania and Africa.

### ◆ Subsidiaries and Affiliates (\*)

(Billions of Yen)

	FY08	FY09	FY10	FY11	FY2011 1-2Q Total	FY2012 1-2Q Total	vs FY2011 1-2Q Total	increase/ decrease
Takeda Pharmaceuticals U.S.A., Inc.	510.2	460.9	400.2	328.5	182.1	<b>140.8</b>	-41.3	-22.7%
[Millions of US\$]	[5,074]	[4,966]	[4,668]	[4,154]	[2,281]	<b>[1,766]</b>	[-514]	[-22.6%]
Millennium Pharmaceuticals, Inc.	59.4	71.4	74.7	87.3	42.3	<b>51.5</b>	9.2	21.8%
[Millions of US\$]	[591]	[769]	[872]	[1,104]	[529]	<b>[646]</b>	[116]	[22.0%]
Wako Pure Chemical Industries, Ltd.	67.0	69.4	70.0	60.2	29.4	<b>29.1</b>	-0.3	-1.1%

(\*) Sales amounts for TPC group's intercompany transaction are subtracted.

◆ Ethical drugs Sales (Consolidated basis)  
(Major items and regional basis)

(Billions of Yen)

Product	Launched	FY08	FY09	FY10	FY11	FY2011 1-2Q Total	FY2012 1-2Q Total	vs. FY2011 1-2Q Total	increase/ decrease	FY2012 Estimate
<b>Leuprorelin</b>										
Worldwide sales		126.1	120.4	116.4	120.7	60.9	<b>57.4</b>	-3.5	-5.8%	113.5
Japan	(92.9)	66.3	65.3	65.9	67.8	33.8	<b>32.9</b>	-0.8	-2.4%	64.0
Americas	(85.5)	17.2	15.8	14.7	16.1	8.5	<b>7.2</b>	-1.3	-15.4%	14.5
Europe	(89.4)	39.8	35.6	31.0	30.5	15.6	<b>13.6</b>	-2.0	-13.1%	29.5
Asia / Other	(91.7)	2.8	3.7	4.8	6.3	3.0	<b>3.6</b>	0.6	21.0%	5.5
<b>Lansoprazole</b>										
Worldwide sales		271.4	216.1	133.6	122.1	62.3	<b>55.9</b>	-6.4	-10.3%	114.0
Japan	(92.12)	70.7	72.3	70.9	76.5	37.6	<b>34.8</b>	-2.8	-7.5%	70.5
Americas	(95.6)	173.1	119.0	42.8	24.3	14.0	<b>13.4</b>	-0.5	-3.8%	27.0
Europe	(91.12)	24.3	21.4	16.4	16.8	8.8	<b>4.8</b>	-4.0	-45.0%	12.0
Asia / Other	(94.8)	3.2	3.4	3.6	4.5	2.0	<b>2.9</b>	0.9	42.4%	4.5
<b>Candesartan</b>										
Worldwide sales		230.3	218.3	218.0	216.3	112.3	<b>89.2</b>	-23.1	-20.6%	169.0
Japan	(99.6)	137.9	132.6	138.0	142.7	70.9	<b>67.3</b>	-3.6	-5.1%	135.0
Americas, Europe, Asia / Other	Americas (98.10) Europe (97.12) Asia / Other (99.1)	92.5	85.8	80.0	73.7	41.4	<b>21.9</b>	-19.5	-47.2%	34.0
<b>Pioglitazone</b>										
Worldwide sales		387.0	383.3	387.9	296.2	171.0	<b>92.0</b>	-79.0	-46.2%	114.0
Japan	(99.12)	48.8	51.2	47.9	31.8	18.9	<b>10.2</b>	-8.7	-46.2%	20.0
Americas	(99.8)	301.7	297.4	306.2	244.5	139.4	<b>75.1</b>	-64.3	-46.1%	81.0
Europe	(00.10)	32.8	31.3	29.5	15.8	10.4	<b>4.3</b>	-6.1	-58.2%	9.0
Asia / Other	(00.7)	3.7	3.3	4.2	4.1	2.3	<b>2.4</b>	0.1	3.3%	4.0

\* Worldwide sales of Candesartan are divided into only two segments, because export sales of this products to licensee are recorded under a single route.

\*\* Effective from the FY2010, a portion of the pricing system for individual products (selling prices to wholesalers) has been revised in Japan. The figures for "FY09" are indicated after adjustment by applying said new pricing system.

\*\*\* Effective from the FY2010, the Accounting Standard for Disclosures about Segments of an Enterprise and Related Information has been adopted. The figures for "FY09" are calculated and indicated after applying said accounting standard.

\*\*\*\* Effective from the FY2012, the regional category of some countries in other than Americas was changed. For fair comparison, the amounts reported in the FY2011 are modified according to the new classification.

◆ Sales of products outside Japan

(Billions of Yen)

	FY08	FY09	FY10	FY11	FY2011 1-2Q Total	FY2012 1-2Q Total	vs. FY2011 1-2Q Total	increase/ decrease	FY2012 Estimate
<b>Amitiza</b>	21.0	19.8	18.6	18.7	9.5	<b>10.7</b>	1.2	12.3%	20.0
<b>Velcade</b>	37.7	46.2	50.8	58.1	28.1	<b>35.7</b>	7.6	27.0%	70.0
<b>Uloric</b>	0.2	4.4	9.1	12.9	6.1	<b>8.1</b>	2.0	33.2%	17.5
<b>Dexilant</b>	0.5	8.5	18.1	24.1	10.8	<b>15.1</b>	4.3	39.9%	34.5
<b>Pantoprazole</b>	-	-	-	38.7	-	<b>36.8</b>	36.8	-	66.5
<b>Daxas</b>	-	-	-	1.3	-	<b>1.4</b>	1.4	-	7.0

◆ Ethical drugs: Major products domestic sales

(Billions of Yen)

Product	Launched	Therapeutic Class	FY08	FY09	FY10	FY11	FY2011 1-2Q Total	FY2012 1-2Q Total	vs. FY2011 1-2Q Total	increase/ decrease	FY2012 Estimate
Blopress	(99. 6)	Hypertension	137.9	132.6	138.0	142.7	70.9	<b>67.3</b>	-3.6	-5.1%	<b>135.0</b>
<Ecard>	(09. 3)	Hypertension	-	0.7	10.4	13.0	6.4	<b>6.3</b>	-0.1	-1.7%	<b>13.0</b>
<Unisia>	(10. 6)	Hypertension	-	-	4.7	17.7	7.7	<b>10.7</b>	3.0	38.6%	<b>22.0</b>
Takepron	(92.12)	Peptic ulcers	70.7	72.3	70.9	76.5	37.6	<b>34.8</b>	-2.8	-7.5%	<b>70.5</b>
Leuplin	(92. 9)	Prostate cancer, breast cancer and endometriosis	66.3	65.3	65.9	67.8	33.8	<b>32.9</b>	-0.8	-2.4%	<b>64.0</b>
Enbrel	(05. 3)	Rheumatoid arthritis	26.3	32.3	38.4	41.4	20.8	<b>21.8</b>	1.0	4.8%	
Nesina	(10. 6)	Diabetes	-	-	1.6	15.5	5.3	<b>15.3</b>	10.0	188.6%	<b>38.0</b>
<Liovel>	(11. 9)	Diabetes	-	-	-	1.0	0.6	<b>1.8</b>	1.2	-	<b>3.0</b>
Actos	(99.12)	Diabetes	48.8	51.2	47.9	31.8	18.9	<b>10.2</b>	-8.7	-46.2%	<b>20.0</b>
Basen	(94. 9)	Diabetes	47.1	41.9	32.2	25.9	13.6	<b>10.2</b>	-3.4	-25.2%	<b>17.5</b>
Vectibix	(10. 6)	Colorectal cancer	-	-	9.4	17.2	8.1	<b>9.6</b>	1.5	18.5%	<b>19.0</b>
Benet	(02. 5)	Osteoporosis	16.3	17.4	17.6	16.5	8.7	<b>6.8</b>	-1.9	-21.5%	<b>15.0</b>
Takeda freeze-dried live attenuated measles / rubella combined	(06. 1)	Vaccine for measles /rubella	8.4	8.2	8.3	8.1	5.1	<b>4.4</b>	-0.7	-14.0%	<b>6.5</b>
Reminyl	(11. 3)	Alzheimer-type dementia	-	-	0.5	2.7	0.9	<b>3.7</b>	2.8	-	
Seltouch	(93. 9)	Topical NSAID	11.3	10.4	8.7	7.8	4.1	<b>3.6</b>	-0.5	-13.1%	<b>8.5</b>
Rozerem	(10. 7)	Insomnia	-	-	1.0	2.5	0.9	<b>2.1</b>	1.2	124.1%	<b>5.0</b>
Azilva	(12. 5)	Hypertension	-	-	-	-	-	<b>1.9</b>	1.9	-	<b>5.0</b>

\* Effective from the FY2010, a portion of the pricing system for individual products (selling prices to wholesalers) has been revised in Japan. The figures for "FY09" are indicated after adjustment by applying said new pricing system.

\*\* The figures for "FY12 Estimate" are partially undisclosed due to disclosure policy of alliance partners.

◆ Consumer Healthcare: Major products sales

(Billions of Yen)

	FY08	FY09	FY10	FY11	FY2011 1-2Q Total	FY2012 1-2Q Total	vs. FY2011 1-2Q Total	increase/ decrease	FY2012 Estimate
Alinamin drink	12.8	12.2	12.7	13.0	7.0	<b>8.0</b>	1.0	14.9%	<b>14.5</b>
Alinamin tablet	14.6	14.6	14.0	14.7	7.8	<b>7.9</b>	0.1	1.7%	<b>15.1</b>
Benza	8.5	7.8	8.7	9.2	5.1	<b>5.3</b>	0.2	4.2%	<b>9.7</b>
Biofermin	7.1	6.6	7.0	7.5	3.6	<b>4.0</b>	0.4	9.9%	<b>7.8</b>
Borraginol	4.3	4.0	4.2	4.3	2.0	<b>2.0</b>	0.0	2.3%	<b>4.4</b>

### 3. Selling, General and Administrative expenses

(Billions of Yen)

	FY08	FY09	FY10	FY11	FY2011 1-2Q Total	FY2012 1-2Q Total	vs FY2011 1-2Q Total	increase/ decrease
<b>SG&amp;A expenses</b>	942.3	760.7	734.7	810.7	331.9	<b>462.3</b>	130.4	39.3%
<% of net sales>	<61.3%>	<51.9%>	<51.8%>	<53.7%>	<47.2%>	<b>&lt;58.7%&gt;</b>	<11.5pt>	
Selling expenses	108.1	94.0	94.5	125.2	46.0	<b>74.8</b>	28.8	62.7%
Advertising expenses	20.3	19.3	24.7	27.1	13.8	<b>10.3</b>	-3.5	-25.2%
Sales promotion expenses	45.6	41.7	43.3	53.1	19.3	<b>28.4</b>	9.1	47.1%
Transportation and custody expenses	8.0	8.5	8.5	11.7	4.3	<b>7.6</b>	3.3	77.4%
Personnel expenses	167.5	174.2	171.8	169.4	75.1	<b>97.6</b>	22.5	30.0%
Other expenses	213.7	196.0	179.6	234.2	91.8	<b>135.1</b>	43.4	47.3%
<b>R&amp;D expenses</b>	453.0	296.4	288.9	281.9	119.0	<b>154.7</b>	35.7	30.0%
<% of net sales>	<29.5%>	<20.2%>	<20.4%>	<18.7%>	<16.9%>	<b>&lt;19.7%&gt;</b>	<2.7pt>	
<b>R&amp;D expenses for ethical drugs</b>	448.1	291.6	283.9	276.9	116.7	<b>151.8</b>	35.1	30.1%
<% of ethical drugs sales>	<32.3%>	<22.1%>	<22.3%>	<20.3%>	<18.6%>	<b>&lt;21.3%&gt;</b>	<2.8pt>	
<b>SG&amp;A expenses except R&amp;D expenses</b>	489.3	464.3	445.8	528.8	212.9	<b>307.6</b>	94.7	44.5%
<% of net sales>	<31.8%>	<31.7%>	<31.4%>	<35.0%>	<30.3%>	<b>&lt;39.1%&gt;</b>	<8.8pt>	

### 4. Non-operating income and expenses

(Billions of Yen)

	FY08	FY09	FY10	FY11	FY2011 1-2Q Total	FY2012 1-2Q Total	vs FY2011 1-2Q Total	increase/ decrease
<b>Non-operating income and expenses</b>	20.7	-4.4	4.5	5.3	-1.5	<b>4.5</b>	6.0	-
<b>Non-operating income</b>	43.1	25.2	30.4	23.4	13.4	<b>13.4</b>	0.1	0.6%
Interest income	11.4	2.0	1.7	1.9	1.0	<b>0.5</b>	-0.5	-48.3%
Dividend income	5.7	4.2	4.5	4.4	2.2	<b>2.2</b>	0.1	2.5%
Equity in earnings of affiliates	2.9	0.8	0.5	0.3	0.1	<b>0.5</b>	0.4	-
Other non-operating income	23.2	18.2	23.8	16.8	10.2	<b>10.2</b>	0.1	0.8%
<b>Non-operating expenses</b>	22.4	29.6	25.9	18.1	14.9	<b>8.9</b>	-5.9	-39.9%
Interest expenses	1.6	1.4	1.3	1.9	0.6	<b>1.5</b>	0.9	-
Loss on inventories	0.4	0.0	0.3	0.2	0.2	<b>0.0</b>	-0.2	-96.7%
Loss on marketable securities	1.9	0.5	0.3	0.1	0.1	<b>0.2</b>	0.2	-
Loss on fixed assets	0.8	2.2	0.9	0.7	0.1	<b>0.6</b>	0.5	-
Contributions	4.4	5.5	4.4	5.3	2.5	<b>0.6</b>	-1.9	-76.5%
Other non-operating expenses	13.3	20.0	18.7	9.9	11.4	<b>6.0</b>	-5.4	-47.7%

### 5. Extraordinary gain and loss

(Billions of Yen)

	FY08	FY09	FY10	FY11	FY2011 1-2Q Total	FY2012 1-2Q Total
<b>Extraordinary gain and loss</b>	71.3	-	-	-17.9	-	<b>17.2</b>
<b>Extraordinary gain</b>	71.3	-	-	17.6	-	<b>28.6</b>
Gain on sale of businesses	71.3	-	-	-	-	-
Gain on sale of property, plant and equipment	0.0	-	-	17.6	-	-
Gain on sale of marketable securities	-	-	-	-	-	<b>17.0</b>
Interest on tax refund	-	-	-	-	-	<b>11.6</b>
<b>Extraordinary loss</b>	-	-	-	35.5	-	<b>11.4</b>
Restructuring costs	-	-	-	35.5	-	<b>11.4</b>